A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.

CONTEXT Prior risk stratification schemes for atrial fibrillation (AF) have been based on randomized trial cohorts or Medicare administrative databases, have included patients with established AF, and have focused on stroke as the principal outcome. OBJECTIVE To derive risk scores for stroke alone and stroke or death in community-based individuals with new-onset AF. DESIGN, SETTING, AND PARTICIPANTS Prospective, community-based, observational cohort in Framingham, Mass. We identified 868 participants with new-onset AF, 705 of whom were not treated with warfarin at baseline. Risk scores for stroke (ischemic or hemorrhagic) and stroke or death were developed with censoring when warfarin initiation occurred during follow-up. Event rates were examined in low-risk individuals, as defined by the risk score and 4 previously published risk schemes. MAIN OUTCOME MEASURES Stroke and the combination of stroke or death. RESULTS During a mean follow-up of 4.0 years free of warfarin use, stroke alone occurred in 83 participants and stroke or death occurred in 382 participants. A risk score for stroke was derived that included the following risk predictors: advancing age, female sex, increasing systolic blood pressure, prior stroke or transient ischemic attack, and diabetes. With the risk score, 14.3% of the cohort had a predicted 5-year stroke rate < or =7.5% (average annual rate < or =1.5%), and 30.6% of the cohort had a predicted 5-year stroke rate < or =10% (average annual rate < or =2%). Actual stroke rates in these low-risk groups were 1.1 and 1.5 per 100 person-years, respectively. Previous risk schemes classified 6.4% to 17.3% of subjects as low risk, with actual stroke rates of 0.9 to 2.3 per 100 person-years. A risk score for stroke or death is also presented. CONCLUSION These risk scores can be used to estimate the absolute risk of an adverse event in individuals with AF, which may be helpful in counseling patients and making treatment decisions.

[1]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[2]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[3]  Ralph B D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions. , 2005, Statistics in medicine.

[4]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[5]  Z. Yuan,et al.  Risk of stroke in patients with atrial flutter. , 2001, The American journal of cardiology.

[6]  G. Lip,et al.  Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.

[7]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[8]  Predictors of Thromboembolism in Atrial Fibrillation: II. Echocardiographic Features of Patients at Risk , 1992, Annals of Internal Medicine.

[9]  A R Feinstein,et al.  Risk for systemic embolization of atrial fibrillation without mitral stenosis. , 1990, The American journal of cardiology.

[10]  D L Rosman,et al.  Atrial fibrillation and mortality in an elderly population. , 1989, Australian and New Zealand journal of medicine.

[11]  P. Wolf,et al.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke , 1978, Neurology.

[12]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.

[13]  R. Hart,et al.  Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention , 1999, Annals of Internal Medicine.

[14]  Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. , 1998, Archives of internal medicine.

[15]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.

[16]  R. Tracy,et al.  Plasmin-α2-antiplasmin Complex in Patients with Atrial Fibrillation , 1999, Thrombosis and Haemostasis.

[17]  L. Kalra,et al.  Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation. , 1999, Stroke.

[18]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[19]  R. D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions , 2004, Statistics in medicine.

[20]  T. Koepsell,et al.  Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease. , 2003, JAMA.

[21]  J. Halperin,et al.  Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. , 2000, The American journal of medicine.

[22]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[23]  Daniel Levy,et al.  Arrhythmias: abstractA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study☆ , 2003 .

[24]  V. Fuster,et al.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.

[25]  H. Sies,et al.  Vascular effects of cocoa rich in flavan-3-ols. , 2003, JAMA.

[26]  Carl van Walraven,et al.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. , 2002, JAMA.

[27]  S. Fihn,et al.  The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.

[28]  B. Drew,et al.  Risk of thromboembolism in chronic atrial flutter. , 1997, The American journal of cardiology.

[29]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[30]  R. Kronmal,et al.  Stroke risk in an elderly population with atrial fibrillation , 1999, Journal of General Internal Medicine.

[31]  A. Laupacis,et al.  A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. , 2003, Archives of internal medicine.

[32]  R. Cheung.  Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. , 1998, JAMA.

[33]  Richard B. Devereux,et al.  Correlates of Left Atrial Size in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study , 2002, Hypertension.

[34]  W. Kannel,et al.  Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. , 1969, Annals of internal medicine.

[35]  P. T. Onundarson,et al.  Chronic atrial fibrillation--epidemiologic features and 14 year follow-up: a case control study. , 1987, European heart journal.

[36]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[37]  J. Hirsh,et al.  Management of anticoagulation before and after elective surgery. , 1997, The New England journal of medicine.

[38]  J. Senges,et al.  Risk of thromboembolic events in patients with atrial flutter. , 1998, The American journal of cardiology.

[39]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[40]  L. Kalra,et al.  Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? , 2001, Archives of internal medicine.

[41]  J. Halperin,et al.  Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. , 2000, Journal of the American College of Cardiology.